ARION adds to the negative IO+CRT story in esophageal cancer. Durvalumab + FOLFOX/50 Gy in 25 fx: PFS HR 0.91 (95% CI 0.55-1.49), OS HR 0.99. Only 112 pts, mostly SCC. No demonstrated benefit from adding durva here. #ESMO26 #radonc https://t.co/Pu9UrF0lrp https://t.co/EpbsJUnuQf